Olinvacimab With Pembrolizumab in Patients With mTNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Triple-Negative Breast Cancer
Interventions: DRUG: Olinvacimab
Sponsor: PharmAbcine
Collaborators: Merck Sharp & Dohme LLC